During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

European countries must match ambition with action — and reward the kind of pharmaceutical innovation they say they want to lead.